Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...
Investor's Business Daily on MSN5h
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity ShotAmgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
The monthly price of Wegovy varies from 1,313 crowns for a starter dose, to 2,353 crowns for the maximum maintenance dose, according to the website of the Danish medicines agency. The number of ...
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...
25 mg starter dose of semaglutide-based obesity med Wegovy is now available in the U.S. In October, Novo Nordisk shared data from the SOUL Phase 3 cardiovascular outcomes trial that evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback